دورية أكاديمية
أعرض في EDS

Calix[ n ]arene-based immunogens: A new non-proteic strategy for anti-cocaine vaccine.

التفاصيل البيبلوغرافية
العنوان: Calix[ n ]arene-based immunogens: A new non-proteic strategy for anti-cocaine vaccine.
المؤلفون: da Silva Neto L; Department of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., da Silva Maia AF; Department of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Godin AM; Department of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., de Almeida Augusto PS; Department of Mental Health, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, MG, Brazil., Pereira RLG; Department of Mental Health, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, MG, Brazil., Caligiorne SM; Department of Mental Health, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, MG, Brazil., Alves RB; Department of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Fernandes SOA; Department of Clinical & Toxicological Analysis, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Cardoso VN; Department of Clinical & Toxicological Analysis, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Goulart GAC; Department of Pharmaceutics, Faculty of Pharmacy, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil., Martins FT; Institute of Chemistry, Universidade Federal de Goiás, Goiânia 74690-900, MG, Brazil., das Neves MCL; Department of Mental Health, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, MG, Brazil., Garcia FD; Department of Mental Health, Universidade Federal de Minas Gerais, Belo Horizonte 30130-100, MG, Brazil., de Fátima Â; Department of Chemistry, Institute of Exact Sciences, Universidade Federal de Minas Gerais, Belo Horizonte 31270-901, MG, Brazil.
المصدر: Journal of advanced research [J Adv Res] 2021 Sep 13; Vol. 38, pp. 285-298. Date of Electronic Publication: 2021 Sep 13 (Print Publication: 2022).
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: Cairo University, production and hosting by Elsevier B. V Country of Publication: Egypt NLM ID: 101546952 Publication Model: eCollection Cited Medium: Internet ISSN: 2090-1224 (Electronic) Linking ISSN: 20901224 NLM ISO Abbreviation: J Adv Res Subsets: MEDLINE
أسماء مطبوعة: Original Publication: [Giza, Egypt] : Cairo University, production and hosting by Elsevier B. V.
مواضيع طبية MeSH: Calixarenes*/chemistry , Calixarenes*/pharmacology , Cocaine* , Vaccines*, Animals ; Haptens ; Tissue Distribution
مستخلص: Introduction: Cocaine use disorder is a significant public health issue without a current specific approved treatment. Among different approaches to this disorder, it is possible to highlight a promising immunologic strategy in which an immunogenic agent may reduce the reinforcing effects of the drug if they are able to yield sufficient specific antibodies capable to bind cocaine and/or its psychoactive metabolites before entering into the brain. Several carriers have been investigated in the anti-cocaine vaccine development; however, they generally present a very complex chemical structure, which potentially hampers the proper assessment of the coupling efficiency between the hapten units and the protein structure.
Objectives: The present study reports the design, synthesis and preclinical evaluation of two novel calix[ n ]arene-based anti-cocaine immunogens (herein named as V4N2 and V8N2 ) by the tethering of the hydrolysis-tolerant hapten GNE ( 15 ) on calix[4]arene and calix[8]arene moieties.
Methods: The preclinical assessment corresponded to the immunogenicity and dose-response evaluation of V4N2 and V8N2 . The potential of the produced antibodies to reduce the passage of cocaine analogue through the blood-brain-barrier (BBB), modifying its biodistribution was also investigated.
Results: Both calix[ n ]arene-based immunogens elicited high titers of cocaine antibodies that modified the biodistribution of a cocaine radiolabeled analogue ( 99m Tc-TRODAT-1) and decreased cocaine-induced behavior, according to an animal model.
Conclusion: The present results demonstrate the potential of V4N2 and V8N2 as immunogens for the treatment of cocaine use disorder.
Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
(© 2022 The Authors. Published by Elsevier B.V. on behalf of Cairo University.)
References: Expert Opin Emerg Drugs. 2015 Mar;20(1):15-29. (PMID: 25425416)
Curr Opin Immunol. 1992 Aug;4(4):454-9. (PMID: 1388847)
J Am Chem Soc. 2017 Jun 28;139(25):8601-8611. (PMID: 28574716)
Curr Drug Abuse Rev. 2010 Mar;3(1):49-62. (PMID: 20088819)
Bioconjug Chem. 2013 Oct 16;24(10):1710-20. (PMID: 24041198)
Int J Neuropsychopharmacol. 2008 May;11(3):425-38. (PMID: 17927843)
Neuropsychopharmacology. 2013 Oct;38(11):2170-8. (PMID: 23660705)
Mol Pharm. 2013 Nov 4;10(11):4176-84. (PMID: 23927436)
Int Immunopharmacol. 2016 Jun;35:137-141. (PMID: 27039212)
Trends Psychiatry Psychother. 2019 Jul 15;41(2):186-190. (PMID: 31314858)
Addiction. 2002 Aug;97(8):931-49. (PMID: 12144591)
Braz J Psychiatry. 2018 Oct-Dec;40(4):354-360. (PMID: 29451589)
Biol Psychiatry. 2005 Jul 15;58(2):158-64. (PMID: 16038686)
Nat Med. 1996 Oct;2(10):1129-32. (PMID: 8837612)
Drug Alcohol Depend. 1997 Dec 15;48(3):153-8. (PMID: 9449013)
Expert Rev Vaccines. 2010 Sep;9(9):1109-14. (PMID: 20822352)
J Am Chem Soc. 2011 May 4;133(17):6587-95. (PMID: 21473576)
Pharmacol Rev. 2016 Jul;68(3):533-62. (PMID: 27255266)
Vaccine. 2002 Jan 15;20(7-8):1196-204. (PMID: 11803082)
Neuropharmacology. 2019 Nov 1;158:107730. (PMID: 31369740)
Mol Pharm. 2015 Feb 2;12(2):653-62. (PMID: 25531528)
PLoS One. 2008 Jun 25;3(6):e2547. (PMID: 18575629)
Drug Discov Today. 2020 Mar;25(3):610-619. (PMID: 31419495)
Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1988-92. (PMID: 11172063)
J Nucl Med. 1998 Dec;39(12):2069-76. (PMID: 9867143)
J Am Chem Soc. 2011 Feb 2;133(4):958-63. (PMID: 21158442)
J Med Chem. 2011 Jul 28;54(14):5195-204. (PMID: 21692508)
Chem Biol Drug Des. 2014 Sep;84(3):354-63. (PMID: 24803171)
Eur J Immunol. 1995 Dec;25(12):3445-51. (PMID: 8566036)
Proc Natl Acad Sci U S A. 2013 May 28;110(22):9036-41. (PMID: 23650354)
Int J Immunopharmacol. 2000 Oct;22(10):809-19. (PMID: 10963853)
Angew Chem Int Ed Engl. 2016 Mar 7;55(11):3772-5. (PMID: 26879590)
Subst Use Misuse. 2010 Nov;45(13):2291-300. (PMID: 20394505)
Addict Behav. 2014 Jan;39(1):297-301. (PMID: 24455783)
J Pharmacol Exp Ther. 2019 Feb;368(2):282-291. (PMID: 30409833)
Bioconjug Chem. 2008 Mar;19(3):751-8. (PMID: 18293897)
Psychopharmacology (Berl). 2000 Feb;148(3):251-62. (PMID: 10755738)
Drug Alcohol Depend. 2013 Apr 1;129(1-2):41-8. (PMID: 23022610)
Arch Gen Psychiatry. 2009 Oct;66(10):1116-23. (PMID: 19805702)
Can J Public Health. 2005 May-Jun;96(3):185-8. (PMID: 15913081)
J Pediatr (Rio J). 2019 Mar - Apr;95(2):209-216. (PMID: 29526482)
Vaccines (Basel). 2016 Apr 19;4(2):. (PMID: 27104575)
PLoS One. 2014 Dec 23;9(12):e115696. (PMID: 25536404)
J Addict Dis. 1993;12(2):109-27. (PMID: 8476937)
Methods Mol Biol. 2011;789:295-302. (PMID: 21922416)
Org Lett. 2003 Dec 25;5(26):5071-4. (PMID: 14682767)
Biol Psychiatry. 2013 Apr 15;73(8):721-8. (PMID: 23098894)
Nature. 1995 Dec 14;378(6558):727-30. (PMID: 7501020)
Am J Addict. 2019 Feb;28(2):119-126. (PMID: 30701618)
Bioconjug Chem. 2015 May 20;26(5):791-801. (PMID: 25822926)
J Am Chem Soc. 2006 Nov 15;128(45):14528-36. (PMID: 17090036)
Pharmacol Ther. 2013 Aug;139(2):289-300. (PMID: 23631821)
J Am Chem Soc. 2006 Mar 1;128(8):2715-25. (PMID: 16492059)
CNS Neurol Disord Drug Targets. 2011 Dec;10(8):899-904. (PMID: 22229312)
ACS Chem Neurosci. 2016 May 18;7(5):546-52. (PMID: 26926328)
Braz J Psychiatry. 2006 Sep;28(3):196-202. (PMID: 17063219)
Vaccine. 2010 Mar 2;28(10):2161-2168. (PMID: 20060511)
Neuropsychopharmacology. 2012 Apr;37(5):1083-91. (PMID: 21918504)
Mol Ther. 2011 Mar;19(3):612-9. (PMID: 21206484)
J Med Chem. 2013 May 9;56(9):3701-9. (PMID: 23627877)
Science. 1993 Nov 26;262(5138):1448-51. (PMID: 8248784)
فهرسة مساهمة: Keywords: Calixarenes; Chemical addiction; Cocaine; Crack; Immunotherapy; TRODAT-1
المشرفين على المادة: 0 (Haptens)
0 (Vaccines)
130036-26-9 (Calixarenes)
I5Y540LHVR (Cocaine)
تواريخ الأحداث: Date Created: 20220516 Date Completed: 20220519 Latest Revision: 20240827
رمز التحديث: 20240827
مُعرف محوري في PubMed: PMC9091763
DOI: 10.1016/j.jare.2021.09.003
PMID: 35572397
قاعدة البيانات: MEDLINE
الوصف
تدمد:2090-1224
DOI:10.1016/j.jare.2021.09.003